Xenon Pharmaceuticals Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
XENE$41.39+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of U.S. dollars)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(323,473) | $(240,649) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Interest receivable and accretion of discounts on marketable securities | (4,129) | 6,682 |
| Depreciation of property, plant and equipment | 1,707 | 1,932 |
| Non-cash operating lease expense | 993 | 979 |
| Deferred income tax recovery | (2,595) | (2,084) |
| Stock-based compensation expense | 50,175 | 39,592 |
| Unrealized foreign exchange gain | (626) | (88) |
| Realized (gain) loss on marketable securities | (667) | 607 |
| Changes in operating assets and liabilities: | ||
| Other receivables | 200 | 663 |
| Prepaid expenses and other assets | 331 | (9,785) |
| Accounts payable and accrued liabilities | 4,414 | 2,318 |
| Operating lease liability | (1,078) | (962) |
| Other liabilities | 131 | 3,158 |
| Net cash used in operating activities | (274,617) | (197,637) |
| Investing activities: | ||
| Purchases of property, plant and equipment | (692) | (481) |
| Purchases of marketable securities | (1,165,645) | (294,757) |
| Proceeds from marketable securities | 481,009 | 450,539 |
| Net cash provided by (used in) investing activities | (685,328) | 155,301 |
| Financing activities: | ||
| Proceeds from offerings, net | 837,526 | — |
| Proceeds from exercise of stock options | 5,741 | 3,576 |
| Net cash provided by financing activities | 843,267 | 3,576 |
| Effect of exchange rate changes on cash and cash equivalents | 75 | 562 |
| Decrease in cash and cash equivalents | (116,603) | (38,198) |
| Cash and cash equivalents, beginning of period | 199,163 | 142,712 |
| Cash and cash equivalents, end of period | $82,560 | $104,514 |
| Supplemental disclosure of cash paid: | ||
| Operating lease | $1,333 | $1,280 |
| Income taxes | $1,004 | $9,542 |
| Supplemental disclosures of non-cash transactions: | ||
| Fair value of stock options and pre-funded warrants exercised on a cashless basis | $87,942 | $12,567 |
-6-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.